Patel Rita V, Frankel Amylynne, Goldenberg Gary
Department of Dermatology, Mount Sinai School of Medicine, New York, New York.
J Clin Aesthet Dermatol. 2011 Feb;4(2):20-7.
Estimates from the American Cancer Society suggest that there are more than two million cases of nonmelanoma skin cancer in the United States per year. The following review highlights the topics of actinic keratoses, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, and Merkel cell carcinoma. This update on the cutting-edge clinical and dermpathologic research will assist the dermatologist in approaching, diagnosing, and managing nonmelanoma skin carcinoma. Immunologic and genetic research into nonmelanoma skin carcinoma has paved the way for novel therapeutic options for patients who were previously without any viable treatment alternatives. While still in preliminary stages, agents, such as ingenol mebutate, vismodegib, and sirolumus, may become integral drugs in the armamentarium of managing cutaneous carcinoma.
美国癌症协会的估计表明，美国每年有超过两百万例非黑色素瘤皮肤癌病例。以下综述重点介绍光化性角化病、基底细胞癌、鳞状细胞癌、卡波西肉瘤和默克尔细胞癌等主题。这一关于前沿临床和皮肤病理学研究的更新将有助于皮肤科医生对非黑色素瘤皮肤癌进行评估、诊断和管理。对非黑色素瘤皮肤癌的免疫和基因研究为以前没有任何可行治疗选择的患者开辟了新的治疗途径。虽然仍处于初步阶段，但诸如 ingenol mebutate、vismodegib 和西罗莫司等药物可能会成为治疗皮肤癌的重要药物。
